As any needle-phobic patient can tell you, a big part of medicine involves getting past the skin barrier. It’s an issue for getting medicine in, or getting blood out, and it’s more than a painful irritation. For people who have special needs, such as continuous glucose monitoring, needles can represent a major quality of life issue, a serious need now being addressed by a new technology offered through Echo Therapeutics, Inc.
Echo Therapeutics is a Pennsylvania based medical device company, with a deep expertise in advanced skin permeation technology. The company’s primary technology is its Prelude® SkinPrep System, a platform for enhanced and painless skin permeation, targeting two widespread uses:
• Needle-Free Drug Delivery, with the delivery of lidocaine, a common local anesthetic and antiarrhythmic drug, as the initial application
• Analyte Extraction, using the Symphony® tCGM System for needle-free, continuous glucose monitoring in hospital patients as the first application
Echo has enjoyed significant share-price growth, rising from $0.212 in late 2008 to nearly exceed $5.00 earlier this year, with additional applications for painless needle-free drug delivery already being planned.
One of Echo’s key directors, and a past president of the company, is Shawn Singh, currently the CEO of VistaGen Therapeutics (OTCBB: VSTA), a growing biotechnology company focused on using proprietary stem cell technologies for drug rescue. Mr. Singh, an honors graduate of U.C. Berkeley with a J.D. from the University of Maryland School of Law, has been working with life science companies for nearly 20 years. He has also served as CEO and director of Hemodynamics Therapeutics, a majority owned affiliate of Cato BioVentures.
For additional information on Echo Therapeutics, visit www.EchoTx.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
